MedPath

Evaluation of SenseGuard™- a Noninvasive Respiratory Rate Measuring Device

Not Applicable
Completed
Conditions
Condition
Interventions
Device: SenseGuard
Registration Number
NCT03964675
Lead Sponsor
NanoVation
Brief Summary

The SenseGuard™ is a new respiratory rate measuring and logging non-invasive device, and measures the respiratory rate by responding to changes in air moisture content in exhaled air. A prospective single-center, single arm study, designed to assess the bias, accuracy , precision and safety of the SenseGuard™ device in measuring of respiratory rate in adult patients. The study shall include a single invitational visit with a respiratory rate measurement duration of 30 minutes for each of 25 adult subjects hospitalized in internal wards.Subjects will be invited to participate should they meet all of the eligibility criteria. Following informed consent, subjects will be measured with both Microstream capnograph and SenseGuard™ measuring simultaneously so their results can be compared.

Detailed Description

Study description:

Respiratory rate (RR) is a vital sign used to monitor clinical condition of a patient. It is defined as the number of breaths per minute. Various devices using different techniques are available to measure RR. Currently this is measured at the bedside in clinical practice by counting the breaths, however the gold standard for measuring this vital sign is the capnograph. For the patient, this involves limiting the movement and talking so that the measurements can be taken.

A new respiratory rate measuring and logging device, SenseGuard™, is non-invasive and measures the respiratory rate by responding to changes in air moisture content (small amounts of water condensation) in exhaled air.

The study is planned as a prospective single-center, single arm study, designed to assess the bias, accuracy , precision and safety of the SenseGuard™ non-invasive device in measuring of respiratory rate in adult patients.

Subjects will be invited to participate should they meet all of the eligibility criteria. Following informed consent, subjects will be measured with both Microstream capnograph and SenseGuard™ measuring simultaneously so their results can be compared.

Study population:

25 hospitalized patients from Internal/General wards aged 18 and older.

Objective:

Evaluate the performance and safety of the SenseGuard™ non-invasive device in measuring respiratory rate in hospitalized adult patients.

Inclusion Criteria:

1. Hospitalized patients from the Internal/General wards.

2. Provision of signed and dated informed consent form

3. Stated willingness to comply with all study procedures and availability for the duration of the study

4. Male or female, aged ≥18

5. Willing to adhere to the study regimen

Exclusion Criteria:

1. Intubated patients (i.e. endobronchial intubation) or patients currently undergoing a BPAP/CPAP treatment.

2. Presence of implanted electronic device intended to regulate cardiac activity (e.g., pacemaker or cardioverter/defibrillator)

3. Pregnancy or lactation

4. Known allergic reactions to materials used in the components of the SenseGuard™ system, i.e. polyethylene or silicon, or gold, nickel, copper or alloys containing any of the above.

5. Participation in another study in the last 4 weeks

Participant Duration:

A single invitational visit with a respiratory rate measurement duration of 30 minutes

Study Duration:

1 year.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  1. Hospitalized patients from the Internal/General wards.
  2. Provision of signed and dated informed consent form
  3. Stated willingness to comply with all study procedures and availability for the duration of the study
  4. Male or female, aged ≥18
  5. Willing to adhere to the study regimen
Exclusion Criteria
  1. Intubated patients (i.e. endobronchial intubation) or patients currently undergoing a BPAP/CPAP treatment.
  2. Presence of implanted electronic device intended to regulate cardiac activity (e.g., pacemaker or cardioverter/defibrillator)
  3. Pregnancy or lactation
  4. Known allergic reactions to materials used in the components of the SenseGuard™ system, i.e. polyethylene or silicon, or gold, nickel, copper or alloys containing any of the above.
  5. Participation in another study in the last 4 weeks

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Respiratory rate measurementSenseGuardSimultaneous measurement of respiratory rate using SenseGuard and Capnography
Primary Outcome Measures
NameTimeMethod
Accuracy of Respiratory Rate (RR) as measured by the SenseGuard™ system versus the gold standard (capnography).4 months
Frequency and incidence of any adverse events and serious adverse events related and unrelated to the device use4 months
Secondary Outcome Measures
NameTimeMethod
Usability (comfort and easiness) score of the SenseGuard™ system as measured by a questionnaire completed by the subjects4 months

The easiness and comfort shall be evaluated using a questionnaire that includes 5 questions with possible scores ranging from 1(worst)-5(best)

Trial Locations

Locations (1)

Galilee Medical Center

🇮🇱

Nahariya, Israel

© Copyright 2025. All Rights Reserved by MedPath